Fulgent Genetics (NASDAQ:FLGT) Sets New 52-Week Low at $21.20

Shares of Fulgent Genetics, Inc. (NASDAQ:FLGT - Get Free Report) hit a new 52-week low on Monday . The stock traded as low as $21.20 and last traded at $21.23, with a volume of 41521 shares changing hands. The stock had previously closed at $21.70.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Piper Sandler dropped their target price on Fulgent Genetics from $28.00 to $25.00 and set a "neutral" rating for the company in a report on Wednesday, March 6th. UBS Group assumed coverage on Fulgent Genetics in a report on Thursday, December 7th. They issued a "neutral" rating and a $35.00 price objective for the company.

Fulgent Genetics Trading Up 0.6 %

The company has a market cap of $652.42 million, a PE ratio of -3.87 and a beta of 1.43. The stock has a 50 day moving average price of $23.90 and a 200 day moving average price of $25.99.

Fulgent Genetics (NASDAQ:FLGT - Get Free Report) last released its earnings results on Wednesday, February 28th. The company reported ($0.02) EPS for the quarter, beating analysts' consensus estimates of ($0.63) by $0.61. The company had revenue of $70.51 million during the quarter, compared to analysts' expectations of $67.14 million. Fulgent Genetics had a negative return on equity of 3.04% and a negative net margin of 58.03%. Equities analysts expect that Fulgent Genetics, Inc. will post -2.04 EPS for the current fiscal year.

Hedge Funds Weigh In On Fulgent Genetics

Several large investors have recently made changes to their positions in FLGT. BlackRock Inc. grew its stake in shares of Fulgent Genetics by 3.4% in the first quarter. BlackRock Inc. now owns 3,646,420 shares of the company's stock worth $113,841,000 after acquiring an additional 118,638 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Fulgent Genetics by 11.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,447,153 shares of the company's stock valued at $41,839,000 after acquiring an additional 147,505 shares during the period. Vanguard Group Inc. grew its stake in shares of Fulgent Genetics by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 1,416,191 shares of the company's stock worth $40,942,000 after acquiring an additional 22,480 shares during the period. Finally, State Street Corp grew its stake in shares of Fulgent Genetics by 5.3% in the third quarter. State Street Corp now owns 756,357 shares of the company's stock worth $28,832,000 after acquiring an additional 38,121 shares during the period. 48.06% of the stock is currently owned by hedge funds and other institutional investors.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.